Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

347
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
347
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

261
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
261
Disorders of Hemostasis01:24

Disorders of Hemostasis

2.8K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.8K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.5K
Coagulation01:09

Coagulation

12.2K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
12.2K
Coagulation01:06

Coagulation

1.7K
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The kinetics and interplay of thrombin inhibition by 4 plasma proteinase inhibitors.

Blood vessels, thrombosis & hemostasis·2025
Same author

True anticoagulation safety cannot be achieved without better anticoagulants.

BMJ open quality·2025
Same author

Recombinant factor VIIa: new insights into the mechanism of action through product innovation.

Research and practice in thrombosis and haemostasis·2025
Same author

Modelling the effects of 4-factor prothrombin complex concentrate for the management of factor Xa-associated bleeding.

PloS one·2024
Same author

Ultrasoft platelet-like particles stop bleeding in rodent and porcine models of trauma.

Science translational medicine·2024
Same author

Emicizumab promotes factor Xa generation on endothelial cells.

Journal of thrombosis and haemostasis : JTH·2024
Same journal

Bridging the Gap in Laboratory Monitoring of Extended Half-Life Factor VIII and IX: Can Thrombin Generation Assays Overcome Assay Discrepancies?

Seminars in thrombosis and hemostasis·2026
Same journal

External Quality Assessment for Low Molecular Weight Heparin Monitoring in the Australasia/Asia-Pacific Region.

Seminars in thrombosis and hemostasis·2026
Same journal

Human evolution: between hemorrhage and thrombosis.

Seminars in thrombosis and hemostasis·2026
Same journal

Full- vs Reduced-Dose Direct Oral Anticoagulants for Extended Treatment of Cancer-Associated Thrombosis: A Multicenter Retrospective Cohort Study.

Seminars in thrombosis and hemostasis·2026
Same journal

Too Old for PESI?: Risk Stratification of Octogenarians with Pulmonary Embolism in the Emergency Department.

Seminars in thrombosis and hemostasis·2026
Same journal

Acute Management and Bleeding Outcomes in Pediatric Pulmonary Embolism: A Large Single-Center Retrospective Cohort Study.

Seminars in thrombosis and hemostasis·2026
See all related articles

Related Experiment Video

Updated: Apr 11, 2026

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo
06:23

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo

Published on: August 4, 2018

9.3K

Coagulation in Liver Disease.

Maureane Hoffman1

  • 1Pathology and Laboratory Medicine Service, Durham Veterans Affairs Medical Center, Durham, North Carolina.

Seminars in Thrombosis and Hemostasis
|June 7, 2015
PubMed
Summary
This summary is machine-generated.

Traditional liver function tests like prothrombin time (PT) and activated partial thromboplastin time (aPTT) do not fully capture bleeding or clotting risks in liver failure patients. These tests overlook cellular roles and antithrombotic/fibrinolytic systems crucial for hemostasis.

More Related Videos

New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation
08:45

New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation

Published on: June 27, 2025

1.9K
Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

11.3K

Related Experiment Videos

Last Updated: Apr 11, 2026

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo
06:23

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo

Published on: August 4, 2018

9.3K
New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation
08:45

New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation

Published on: June 27, 2025

1.9K
Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

11.3K

Area of Science:

  • Biochemistry
  • Hematology
  • Physiology

Background:

  • The liver synthesizes key proteins for coagulation, antithrombosis, and fibrinolysis, essential for hemostasis.
  • Traditional laboratory tests, prothrombin time (PT) and activated partial thromboplastin time (aPTT), are based on in vitro plasma clotting.
  • Current understanding emphasizes the active, localized regulation of hemostasis by cellular elements.

Purpose of the Study:

  • To evaluate the limitations of PT and aPTT in reflecting hemostasis in liver failure.
  • To highlight the importance of cellular components and regulatory systems in hemostasis.
  • To determine if PT accurately predicts bleeding or thrombosis risk in liver disease.

Main Methods:

  • Review of established models of hemostasis.
  • Analysis of the components measured by PT and aPTT.
  • Comparison of traditional assays with the complex in vivo hemostatic process.

Main Results:

  • PT and aPTT do not account for cellular contributions to hemostasis.
  • These tests do not reflect the roles of antithrombotic and fibrinolytic systems.
  • Liver synthetic function, reflected by PT, does not correlate with bleeding or thrombosis risk in liver failure.

Conclusions:

  • PT and aPTT are insufficient for assessing hemostatic competence in liver failure.
  • A comprehensive understanding of hemostasis requires considering cellular and regulatory systems.
  • Newer diagnostic approaches are needed to accurately predict bleeding and thrombosis risk in patients with liver disease.